Cell Biology

RSS

Lipid signaling pathway helps cells survive bacterial toxin damage

Epithelial cells form the body's frontline barriers, helping keep microbes, toxins, and other harmful substances out.

5 Oct 2026

New BCR analysis method tracks immune recovery after stem cell transplantation

A research team led by Associate Professor Yohei Funakoshi, Associate Professor Kimikazu Yakushijin, and Professor Hironobu Minami of the Division of Medical Oncology/Hematology at Kobe University Hospital, together with Associate Professor Goh Ohji of the Division of Infectious Disease Therapeutics and Takaji Matsutani of Anymics Inc., has developed the pGen-SHM plot.

5 Oct 2026

Restoring cellular recycling helps the body clear harmful zombie cells

As we grow older, our bodies accumulate "zombie cells"-living cells that have stopped dividing or functioning normally-but linger in our tissues, contributing to chronic inflammation and age-related diseases.

5 Oct 2026

Dana-Farber research reveals possible new target for treatment of sickle cell and beta thalassemia

That pathway involves BACH2 and NRF2 and was discovered using a large genome-wide association study that enabled an analysis of genes related to fetal hemoglobin from a wide range of ancestries, including European, African, and Asian ancestries.

5 Oct 2026

Shift Bioscience publication increases confidence in AI virtual cells for novel target discovery

Shift Bioscience (Shift), a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for age driven diseases, today announced the publication of new research in Nature Biotechnology describing an improved calibration framework for deep learning-based genetic perturbation models.

From Shift Bioscience 5 Oct 2026

Lab-grown human pituitary cells work and survive after transplantation into a primate

Researchers in Japan have transplanted pituitary tissue grown from human stem cells into a primate whose pituitary gland had been surgically removed, successfully restoring critical hormone signals.

1 Oct 2026

Autophagy changes with age, sex and cell type, study finds

Taking out the trash is a chore that even our cells cannot escape. Through a process known as autophagy, they place misshapen proteins and other cellular garbage in biological containers in order to digest them into their molecular building blocks.

1 Oct 2026

Synthetic protein targets TLR4 membrane region to reduce inflammation

To sense their environment and respond accordingly, cells enlist membrane proteins as communication hubs, receiving molecular messages from outside and triggering responses inside.

1 Oct 2026

Loss of tumor suppressor p53 reshapes Wnt signaling to drive mutant cell expansion

A protein known as p53 is, of all tumor suppressors in human cancer, the most frequently altered by gene mutations.

1 Oct 2026

New project explores mitochondrial evolution across diverse life forms

A research consortium has generated the broadest look yet at the proteins that make up mitochondria, capturing the organelle's diversity across multiple branches on the tree of complex life.

1 Oct 2026

Scientists discover new cell type that may help regulate blood vessel growth in the heart

Researchers have discovered a new cell type that may help regulate blood vessel growth in the heart during development and in response to injury, according to a study from Weill Cornell Medicine.

1 Oct 2026

FAU study uses Raman spectroscopy and AI to detect skin cancer

Skin cancer is the most common cancer in the United States and among the most common worldwide. Nearly 1.5 million new cases were diagnosed globally in 2024, including nearly 340,000 melanomas.

1 Oct 2026

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026